Vatinee Y Bunya1, Gui-Shuang Ying1, Maureen G Maguire1, Eric Kuklinski2, Meng C Lin3, Ellen Peskin1, Penny A Asbell2,4. 1. Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY. 3. School of Optometry, University of California, Berkeley, CA. 4. Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN.
Abstract
PURPOSE: To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye. METHODS: Participants underwent ocular surface examinations and serological testing for traditional and novel SS autoantibodies. Dry eye assessment and management participants were categorized into the following 3 groups: 1) no history of SS or other autoimmune diseases and negative traditional SS autoantibodies (n = 352); 2) no history of SS but a history of other autoimmune diseases (n = 66); and 3) those who met the 2012 American College of Rheumatology SS classification criteria (n = 52). RESULTS: Eleven percent had a history of SS, and 6% of those without a history of SS most likely had undiagnosed SS. The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33). Participants who were positive for the traditional autoantibodies alone or positive for both traditional and novel autoantibodies had the highest scores for corneal (P = 0.002) and conjunctival staining (P < 0.001). CONCLUSIONS: Data from this multicenter, prospective study demonstrated that one of the novel candidate autoantibodies, SP-1, is associated with underlying SS and that novel autoantibodies may be associated with worse ocular surface disease. Future longitudinal studies are needed to evaluate their utility in screening patients with dry eye for SS.
PURPOSE: To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye. METHODS:Participants underwent ocular surface examinations and serological testing for traditional and novel SS autoantibodies. Dry eye assessment and management participants were categorized into the following 3 groups: 1) no history of SS or other autoimmune diseases and negative traditional SS autoantibodies (n = 352); 2) no history of SS but a history of other autoimmune diseases (n = 66); and 3) those who met the 2012 American College of Rheumatology SS classification criteria (n = 52). RESULTS: Eleven percent had a history of SS, and 6% of those without a history of SS most likely had undiagnosed SS. The SS group had a higher prevalence of SP-1 autoantibodies than the group without SS or other autoimmune diseases (33% vs. 19%; P = 0.02) but had no difference in carbonic anhydrase 6 (P = 0.31) or parotid secretory protein autoantibodies (P = 0.33). Participants who were positive for the traditional autoantibodies alone or positive for both traditional and novel autoantibodies had the highest scores for corneal (P = 0.002) and conjunctival staining (P < 0.001). CONCLUSIONS: Data from this multicenter, prospective study demonstrated that one of the novel candidate autoantibodies, SP-1, is associated with underlying SS and that novel autoantibodies may be associated with worse ocular surface disease. Future longitudinal studies are needed to evaluate their utility in screening patients with dry eye for SS.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794
Authors: Vatinee Y Bunya; Mina Massaro-Giordano; Frederick B Vivino; Maureen G Maguire; Alan N Baer; John A Gonzales; Gui-Shuang Ying Journal: Cornea Date: 2019-12 Impact factor: 2.651
Authors: Carlos Cifuentes-González; Pilar Uribe-Reina; Juliana Reyes-Guanes; Juliana Muñoz-Ortiz; Paula Tatiana Muñoz-Vargas; William Rojas-Carabali; Dora Victoria Nova-Florián; Ana Sofía De-Los-Ríos; Rubén Dario Mantilla-Hernández; Alejandra de-la-Torre Journal: Clin Ophthalmol Date: 2022-08-09
Authors: John E Sutphin; Gui-Shuang Ying; Vatinee Y Bunya; Yinxi Yu; Meng C Lin; Kathleen McWilliams; Elizabeth Schmucker; Eric J Kuklinski; Penny A Asbell; Maureen G Maguire Journal: Cornea Date: 2021-07-21 Impact factor: 3.152
Authors: Vatinee Y Bunya; Maureen G Maguire; Esen K Akpek; Mina Massaro-Giordano; Sean Hennessy; Frederick B Vivino; John A Gonzales; Alan N Baer; Gui-Shuang Ying Journal: Cornea Date: 2021-02-01 Impact factor: 3.152